Karoon

Karuna Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel therapies for psychiatric and neurological conditions. The company's lead product, Cobenfy (formerly KarXT), is a first-in-class muscarinic antipsychotic that combines xanomeline, a muscarinic agonist, with trospium, a muscarinic antagonist, to minimize peripheral side effects. In March 2024, Karuna was acquired by Bristol Myers Squibb for approximately $14 billion, significantly expanding BMS's neuroscience portfolio. Cobenfy received FDA approval in September 2024 for the treatment of schizophrenia in adults, marking the first new class of antipsychotic medication in decades.